Abdelrahman AlAshqar1, Kristin Patzkowsky2, Sadia Afrin3, Robert Wild4, Hugh S Taylor5, Mostafa A Borahay6. 1. Visitor, Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, MD; Physician, Department of Obstetrics and Gynecology, Kuwait University, Kuwait City, Kuwait. 2. Assistant Professor. 3. Postdoctoral Fellow, Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, MD. 4. Professor, Department of Obstetrics and Gynecology, Oklahoma University, Oklahoma City, OK. 5. Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University, New Haven, CT. 6. Associate Professor, Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, MD.
Abstract
IMPORTANCE: While it has long been known that polycystic ovarian syndrome is associated with cardiometabolic risk factors (CMRFs), there is emerging evidence that other benign gynecologic conditions, such as uterine leiomyomas, endometriosis, and even hysterectomy without oophorectomy, can be associated with CMRFs. Understanding the evidence and mechanisms of these associations can lead to novel preventive and therapeutic interventions. OBJECTIVE: This article discusses the evidence and the potential mechanisms mediating the association between CMRFs and benign gynecologic disorders. EVIDENCE ACQUISITION: We reviewed PubMed, EMBASE, Scopus, and Google Scholar databases to obtain plausible clinical and biological evidence, including hormonal, immunologic, inflammatory, growth factor-related, genetic, epigenetic, atherogenic, vitamin D-related, and dietary factors. RESULTS: Cardiometabolic risk factors appear to contribute to uterine leiomyoma pathogenesis. For example, obesity can modulate leiomyomatous cellular proliferation and extracellular matrix deposition through hyperestrogenic states, chronic inflammation, insulin resistance, and adipokines. On the other hand, endometriosis has been shown to induce systemic inflammation, thereby increasing cardiometabolic risks, for example, through inducing atherosclerotic changes. CONCLUSION AND RELEVANCE: Clinical implications of these associations are 2-fold. First, screening and early modification of CMRFs can be part of a preventive strategy for uterine leiomyomas and hysterectomy. Second, patients diagnosed with uterine leiomyomas or endometriosis can be screened and closely followed for CMRFs and cardiovascular disease.
IMPORTANCE: While it has long been known that polycystic ovarian syndrome is associated with cardiometabolic risk factors (CMRFs), there is emerging evidence that other benign gynecologic conditions, such as uterine leiomyomas, endometriosis, and even hysterectomy without oophorectomy, can be associated with CMRFs. Understanding the evidence and mechanisms of these associations can lead to novel preventive and therapeutic interventions. OBJECTIVE: This article discusses the evidence and the potential mechanisms mediating the association between CMRFs and benign gynecologic disorders. EVIDENCE ACQUISITION: We reviewed PubMed, EMBASE, Scopus, and Google Scholar databases to obtain plausible clinical and biological evidence, including hormonal, immunologic, inflammatory, growth factor-related, genetic, epigenetic, atherogenic, vitamin D-related, and dietary factors. RESULTS: Cardiometabolic risk factors appear to contribute to uterine leiomyoma pathogenesis. For example, obesity can modulate leiomyomatous cellular proliferation and extracellular matrix deposition through hyperestrogenic states, chronic inflammation, insulin resistance, and adipokines. On the other hand, endometriosis has been shown to induce systemic inflammation, thereby increasing cardiometabolic risks, for example, through inducing atherosclerotic changes. CONCLUSION AND RELEVANCE: Clinical implications of these associations are 2-fold. First, screening and early modification of CMRFs can be part of a preventive strategy for uterine leiomyomas and hysterectomy. Second, patients diagnosed with uterine leiomyomas or endometriosis can be screened and closely followed for CMRFs and cardiovascular disease.
Authors: Julianne C Barry; Svetlana Simtchouk; Cody Durrer; Mary E Jung; Alice L Mui; Jonathan P Little Journal: Cytokine Date: 2018-06-06 Impact factor: 3.861
Authors: Anderson Sanches Melo; Julio César Rosa-e-Silva; Ana Carolina Japur de Sá Rosa-e-Silva; Omero Benedicto Poli-Neto; Rui Alberto Ferriani; Carolina Sales Vieira Journal: Fertil Steril Date: 2009-12-06 Impact factor: 7.329
Authors: G Ruotolo; P Båvenholm; K Brismar; S Eféndic; C G Ericsson; U de Faire; J Nilsson; A Hamsten Journal: J Am Coll Cardiol Date: 2000-03-01 Impact factor: 24.094
Authors: Donna D Baird; Greg Travlos; Ralph Wilson; David B Dunson; Michael C Hill; Aimee A D'Aloisio; Stephanie J London; Joel M Schectman Journal: Epidemiology Date: 2009-07 Impact factor: 4.822
Authors: Samvida S Venkatesh; Teresa Ferreira; Stefania Benonisdottir; Nilufer Rahmioglu; Christian M Becker; Ingrid Granne; Krina T Zondervan; Michael V Holmes; Cecilia M Lindgren; Laura B L Wittemans Journal: PLoS Med Date: 2022-02-01 Impact factor: 11.613